1.
Kaminski JA, Schlagenhauf F, Rapp M, et al. Epigenetic variance in dopamine D2 receptor: a marker of IQ malleability?. Transl Psychiatry. 2018;8(1):169. doi:10.1038/s41398-018-0222-7.
1.
Wan Y, Feng G, Calakos N. Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J Neurosci. 2011;31(46):16685-91. doi:10.1523/JNEUROSCI.2533-11.2011.
1.
Weïwer M, Xu Q, Gale JP, et al. Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment. ACS Chem Biol. 2018;13(4):1038-1047. doi:10.1021/acschembio.8b00168.
1.
Nyman ES, Loukola A, Varilo T, et al. Sex-specific influence of DRD2 on ADHD-type temperament in a large population-based birth cohort. Psychiatr Genet. 2012;22(4):197-201. doi:10.1097/YPG.0b013e32834c0cc8.
1.
Chan S, Peterson JD, Gertler TS, et al. Strain-specific regulation of striatal phenotype in Drd2-eGFP BAC transgenic mice. J Neurosci. 2012;32(27):9124-32. doi:10.1523/JNEUROSCI.0229-12.2012.
1.
Cade BE, Gottlieb DJ, Lauderdale DS, et al. Common variants in DRD2 are associated with sleep duration: the CARe consortium. Hum Mol Genet. 2016;25(1):167-79. doi:10.1093/hmg/ddv434.
1.
Zhao B, Zhu J, Dai D, et al. Differential dopaminergic regulation of inwardly rectifying potassium channel mediated subthreshold dynamics in striatal medium spiny neurons. Neuropharmacology. 2016;107:396-410. doi:10.1016/j.neuropharm.2016.03.037.
1.
Dolgin E. Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014;13(9):641-2. doi:10.1038/nrd4411.
1.
Wright J. Genetics: Unravelling complexity. Nature. 2014;508(7494):S6-7. doi:10.1038/508S6a.